The pseudouridine epitranscriptomic landscape of advanced prostate cancer therapeutic resistance identifies TIMM17A as a key player

Abstract

Highlights • PA-Ψ-seq maps pseudouridine remodeling in ARSI resistant ddvanced prostate cancer.• Integrated multi-omics identifies TIMM17A as a driver of ARSI resistance.• PUS1-mediated pseudouridylation of TIMM17A sustains resistance and tumor growth.